- Coccidioides immitis and C. posadasii cause Valley Fever (coccidioidomycosis) — a geographically restricted disease of the American Southwest, parts of Mexico, and Central/South America.
- Approximately 150,000 Americans are infected annually; fewer than half are ever diagnosed, as most cases are misdiagnosed as bacterial pneumonia or other respiratory illness.
- Climate change is expanding the endemic range northward, with cases increasingly reported in previously non-endemic states including Washington and Montana.
- Valley Fever is not contagious between people; infection occurs exclusively by inhaling dust from endemic soil.
- Disseminated coccidioidomycosis — spreading beyond the lungs to bones, meninges, and skin — carries high mortality without lifelong antifungal therapy and is significantly more common in certain ethnic groups (Filipino, African American descent) and immunocompromised individuals.
Coccidioides species cause one of the most distinctive fungal diseases in medicine: Valley Fever, a respiratory illness named for the San Joaquin Valley of California where it was first characterized. The organism is a true environmental pathogen — unlike opportunistic molds, it regularly infects immunocompetent individuals who inhale contaminated desert dust. As climate change expands its range, understanding coccidioidomycosis becomes increasingly relevant beyond the traditional endemic zones.
Taxonomy and Classification
The genus Coccidioides Rixford and Gilchrist belongs to the family Onygenaceae, order Onygenales, class Eurotiomycetes. Two species are recognized: C. immitis (restricted to California, primarily the San Joaquin Valley) and C. posadasii (occurring outside California — Arizona, Texas, Mexico, Central and South America). The two species are clinically indistinguishable; differentiation requires molecular analysis and is primarily of epidemiological rather than clinical importance. Coccidioides is classified as a Select Agent (Tier 3) by the CDC due to its bioterrorism potential — working with the organism requires specialized biosafety laboratory containment.
Remarkable Biology: Arthroconidia and Spherules
Coccidioides has one of the most striking morphological life cycles in mycology — it converts between two radically different forms:
- Mycelial/Environmental Phase: Grows as a mold in desert soil, producing hyphae that segment into barrel-shaped arthroconidia (3–5 × 2–3 μm) separated by empty disjunctor cells. When soil is disturbed and dust becomes airborne, these arthroconidia — among the most infectious fungal particles known — are inhaled.
- Spherule/Parasitic Phase: At human body temperature (37°C), arthroconidia convert into large spherules (20–60 μm in diameter), which internally divide to produce hundreds of endospores. When a spherule ruptures, it releases endospores that each develop into new spherules — a unique, intratissue replication cycle found in no other common human pathogen.
Geographic Distribution and Expansion
The traditional endemic region — the Lower Sonoran Life Zone — is characterized by semi-arid desert conditions with alkaline soil, hot summers, mild winters, and annual rainfall of 5–20 inches. This includes: California’s San Joaquin Valley and southern California, Arizona (Phoenix, Tucson, the Sonoran Desert), southwestern Texas, and northern Mexico. However, coccidioidomycosis cases have been increasingly reported in areas outside the historical endemic zone, including Oregon, Washington, Idaho, and Montana — consistent with the northward and eastward expansion predicted by climate modeling of warming temperatures and altered precipitation patterns.
Clinical Presentations
- Asymptomatic/subclinical: Approximately 60% of primary infections cause no symptoms. Incidentally detected on chest X-ray or seroconversion during contact investigation.
- Acute pulmonary coccidioidomycosis: Flu-like syndrome with fever, cough, chest pain, fatigue, and sometimes a distinctive rash (erythema nodosum or erythema multiforme) appearing 1–3 weeks after exposure. Frequently misdiagnosed as “community-acquired pneumonia” and treated (ineffectively) with antibiotics. Resolves in most otherwise healthy patients.
- Chronic pulmonary coccidioidomycosis: Persistent cavitary or nodular pulmonary disease occurring in approximately 1–5% of symptomatic infections.
- Disseminated coccidioidomycosis: Spread beyond the lungs occurring in less than 1% of all infections overall but substantially more in: Filipino-descent individuals (10–175× higher risk), African-American individuals (increased risk), males, pregnant women (third trimester), and immunocompromised individuals. Sites of dissemination include bones and joints, meninges, and skin. Coccidioidal meningitis is uniformly fatal without lifelong fluconazole therapy.
Diagnosis and Management
Diagnosis relies on serological testing (IgM and IgG antibody detection, with quantitative IgG titers correlating with disease severity and treatment response), antigen testing, and culture (requiring Biosafety Level 2 or 3 precautions). Treatment is with fluconazole or itraconazole for most pulmonary cases; amphotericin B for severe pulmonary or disseminated disease; lifelong fluconazole for meningeal disease.
Frequently Asked Questions
What is Valley Fever?
Valley Fever is the common name for coccidioidomycosis — a respiratory infection caused by inhaling dust containing Coccidioides immitis or C. posadasii spores from endemic desert soil. It ranges from no symptoms (about 60% of infections) to flu-like respiratory illness (most symptomatic cases) to potentially fatal disseminated disease affecting bones, meninges, or other organs (less than 1% overall, but higher in certain groups). An estimated 150,000 Americans are infected annually, with fewer than half ever diagnosed.
Is Valley Fever contagious?
No. Valley Fever is not transmitted from person to person. Infection occurs only by inhaling Coccidioides arthroconidia from contaminated dust in endemic areas. A person with Valley Fever cannot spread it to others through contact, coughing, or any other route of transmission. Rare exceptions have included accidental laboratory exposure (from culture plates) and, in theory, wound infection with contaminated soil material.
Is Valley Fever expanding to new areas?
Yes. Climate modeling and epidemiological data both indicate that the endemic range of Coccidioides is expanding northward. Cases have been reported in Oregon, Washington, Idaho, Montana, and other previously non-endemic states. A 2019 study in GeoHealth projected that by 2100, the endemic range could expand to cover much of the western United States under plausible climate scenarios. Clinicians outside traditional endemic areas are increasingly encountering coccidioidomycosis in patients who have never visited recognized endemic zones.
Why are Filipino and African American individuals at higher risk for severe Valley Fever?
The mechanisms underlying ethnic disparities in coccidioidomycosis severity are not fully established but likely involve genetic variation in immune response pathways, particularly in T-cell and innate immune responses to Coccidioides. Filipino-descent individuals face a 10–175 times higher risk of dissemination than white non-Hispanic individuals of the same immune status — a disparity too large to be explained by socioeconomic or healthcare access differences alone. Research into the genetic basis of these disparities is ongoing.
How long does Valley Fever last?
Most acute pulmonary Valley Fever resolves within 2–6 months without specific antifungal treatment, though profound fatigue can persist for longer. For patients with more severe acute disease, antifungal treatment with fluconazole typically continues for 3–6 months. Chronic pulmonary disease may require years of treatment. Coccidioidal meningitis requires lifelong fluconazole therapy — discontinuing treatment leads to relapse with very high frequency.
